Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-822-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.83 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Thursday, May 16th. Shareholders of record on Friday, July 19th will be paid a dividend of $0.164 per share on Tuesday, September 3rd. This represents a $0.66 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, July 18th. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis announced that its board has authorized a share buyback plan on Wednesday, December 12th 2018, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 4.7% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its stock is undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) posted its quarterly earnings results on Tuesday, August, 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.82 by $0.08. The firm earned $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. Zoetis's revenue was up 9.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 earnings per share. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.
What price target have analysts set for ZTS?
15 Wall Street analysts have issued 12 month target prices for Zoetis' stock. Their predictions range from $86.00 to $145.00. On average, they anticipate Zoetis' stock price to reach $121.4667 in the next year. This suggests that the stock has a possible downside of 3.3%. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
Has Zoetis been receiving favorable news coverage?
Press coverage about ZTS stock has been trending somewhat negative on Saturday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zoetis earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Zoetis.
Are investors shorting Zoetis?
Zoetis saw a increase in short interest in August. As of August 31st, there was short interest totalling 4,326,600 shares, an increase of 9.4% from the July 31st total of 3,953,400 shares. Based on an average daily trading volume, of 2,010,000 shares, the short-interest ratio is presently 2.2 days. Approximately 0.9% of the shares of the stock are sold short. View Zoetis' Current Options Chain.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Allergan (AGN).
What other stocks do shareholders of Zoetis own?
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 68)
- Mr. Glenn C. David, Exec. VP & CFO (Age 47)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
- Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.68%), BlackRock Inc. (7.53%), BlackRock Inc. (7.51%), Morgan Stanley (2.78%), Polen Capital Management LLC (2.13%) and Nuveen Asset Management LLC (1.48%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which major investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., BlackRock Inc., BlackRock Inc., Mackenzie Financial Corp, AQR Capital Management LLC, Marshall Wace LLP, Marshall Wace North America L.P. and Price T Rowe Associates Inc. MD. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which major investors are buying Zoetis stock?
ZTS stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Stonehage Fleming Financial Services Holdings Ltd, Bank of New York Mellon Corp, Vanguard Group Inc., Natixis, Natixis, AKO Capital LLP and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $125.62.
How big of a company is Zoetis?
Zoetis has a market capitalization of $59.99 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
